Audit: QRS - Basil Seeds for Health & Longevity

Audit conducted on 22/08/2026 21:10 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	83
Failed	0
N/A	10
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every populated span traces to ER text: at-a-glance to Conclusion (ER 460–464), protocol cells to Therapeutic Protocol (ER 338–346), time cells to Practical Considerations (ER 391), benefits/risks to the ER tier headings, gates to Key Interactions & Contraindications (ER 292–316), monitoring to the ER biomarker table (ER 421–431).
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	The ER’s hedge on the weight benefit (“⚠️ Conflicted”, ER 164) is carried as “conflicted” in [benefits_medium] (QRS 525).
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Avoid-populations stay absolute in [stop_items] (QRS 542–548); the eight “caution” interactions stay caution-level in [caution_items] (QRS 556–563).
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	All seven [stop_items] map 1:1 to the ER’s “Populations who should avoid Basil Seeds” list (ER 310–316); nothing is drawn from Benefit-Modifying Factors or Risk-Modifying Factors.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, author names, NCT identifiers or brand names appear anywhere in the QRS.
1.6	The QRS does not introduce new attributions.	🟢	The only attributive phrase, “Consumer and Ayurvedic practice converge here” ([action_1_sub], QRS 450), is the ER’s own wording (ER 338).

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, hedged, mechanism-first register matching the ER throughout.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Tiered benefits and risks, concrete targets and cadence, no alarmism and no promotion.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Content is stated as fact and observation, not as instruction to a patient.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	Monitoring cadence and targets are presented as the ER’s protocol description, not as orders.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommend”, “advise”, or “should” in the document’s own voice; the single “should decline” (QRS 720) is the ER’s expectation wording (ER 437).
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronoun occurs anywhere in the file.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Clinical terms are confined to the decision gates and monitoring table where precision is load-bearing; the at-a-glance is plain.
2.8	Information is presented in a concise and very compact manner	🟢	Benefit and risk tiers are single semicolon-separated lines; gate items are one line each.
2.9	It DOES NOT address the reader directly	🟢	Confirmed: no “you”/”your” in the QRS.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range targets (e.g., ApoB below 80 mg/dL, hs-CRP below 1.0 mg/L) and a nine-marker panel address an optimizing reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Pre-soak, pre-meal timing and medication separation are presented without softening for convenience.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No general-population framing; no simplified “superfood” claim.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The at-a-glance states the class-versus-seed evidence gap plainly (QRS 433), which is the distinction that matters to this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	“anti-aging” does not appear; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	“Oral medications generally”, “narrow-therapeutic-index drugs”, “flatulence”, “oesophageal” are used; the plainer at-a-glance wording is required by item 7.4 and is the ER’s own conclusion language.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All present verbatim (QRS 440, 477, 519, 539, 553, 573, 592, 596–598, 711).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	Set comparison against the template shows no template variable missing; the only additions are the repeatable marker_# and qualitative_item_# rows.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A full diff against the template shows changes confined to metadata, <title>, and the checklist-addressed spans.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section feeding a QRS field is empty; every benefit tier, risk tier, gate and monitoring row has ER content.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	Protocol labels “Standard dose”, “Preparation method”, “Best time of day” are verbatim (ER 338, 340, 344); all eight interaction labels including their “(caution; …)” parentheticals are verbatim (ER 292–306).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Monitoring marker names match the ER table column verbatim; the three time-to-effect labels use the ER’s own phrases “Glycemic markers”, “Bowel … effects”, “satiety effects” (ER 391).
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji occurs in the file; the ER’s “⚠️” on the weight benefit is dropped while the word “conflicted” is retained.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Ten ER benefit subsections compress to four lines, six risk subsections to four lines, and interaction drug lists are trimmed to two or three examples each.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Single comment at QRS 2–14, immediately after the doctype.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening “—” at QRS 3, closing “—” at QRS 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	It sits inside an HTML comment and is not duplicated in the header or footer.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, which its colon requires.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	er_filename: basil_seeds_2026-0822-1650_Opus_ER.md (QRS 4).
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	qrs_prompt_version: 26.7.02 (QRS 5), matching the QRS.md badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	qrs_creation_date: 2026-0822-2000 (QRS 6).
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	qrs_creator_ai_nickname: Opus (QRS 7).
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” is a single word with no version or qualifier.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	qrs_creator_ai_fullname: Opus 5 (QRS 8).
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” is nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	qrs_filename: basil_seeds_2026-0822-1650_Opus_QRS.html (QRS 9) matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	“Basil Seeds for Health & Longevity - Quick Reference Sheet” (QRS 22), matching ER canonical_topic (ER 8).
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	“Basil Seeds for Health & Longevity” (QRS 417).
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0822-2000 → “08/22/2026” (QRS 421).
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	“Opus 5” (QRS 425), matching the frontmatter value.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s alternate_names line is not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Four sentences drawn from ER 460–464: mechanism, class evidence, the seed-specific gap, and the mitigable risk profile.
7.2	[at_a_glance] is no longer than 60 words	🟢	52 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“swells into a thick gel that slows” (ER 460), “the evidence is genuinely good … gas and bloating as the price” (ER 460), “almost none of this was measured using basil seeds themselves” (ER 462), “risks are real but largely mechanical … fully soaked … separated in time from medication” (ER 464).
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	No acronyms; “gel-forming fibres”, “blood sugar”, “cholesterol”, “bowel regularity”, “gas and bloating” are self-explanatory.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	No trial name, author, year or sample size appears.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numeric effect, confidence interval or relative risk appears.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All items come from “Populations who should avoid Basil Seeds” (ER 308–316).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All seven ER avoid-population bullets are represented, one per item (QRS 542–548).
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Seven <li> elements inside the span.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Elaborations are stripped: “with delayed emptying on gastric emptying study” (ER 312) and “for whom no human safety data on basil seed intake exist” (ER 315) do not appear; no trailing dash clauses.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“(gastric band, sleeve, bypass pouch)”, “(oregano, thyme, marjoram, mint)” and the staging “(heart failure NYHA Class III–IV, dialysis)” with its 250 ml threshold are all retained (QRS 545, 546, 548).
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names seven avoid-populations, and the section is correctly populated rather than empty.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items come from the ER’s interaction bullets (ER 292–306).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All eight ER interaction bullets are present, and none duplicates a [stop_items] entry.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight <li> elements inside the span.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Mitigation prose such as “Separation of at least two hours before or four hours after the seeds” (ER 292) and “Glucose monitoring at initiation” (ER 296) is stripped; no trailing dash clauses.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Every “(caution; …)” parenthetical is verbatim, and each ER drug list survives in trimmed form (e.g., “levothyroxine, warfarin, digoxin”; “psyllium, chia”; “iron, calcium, zinc”).
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eight interactions, and the section is correctly populated rather than empty.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from Therapeutic Protocol (ER 336–358).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Dose, preparation and timing are the three executable levers; the remaining ER bullets are modifiers or non-applicable pharmacology.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects, so all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	“1–2 teaspoons (5–10 g) daily” (ER 338), “10–15 minute soak” with the 1:10–1:20 ratio and gel halo (ER 340), “10–15 minutes pre-meal” with split dosing (ER 344, 346).

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Glycemic, bowel and satiety are exactly the three the ER names (ER 391).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Glycemic control is the ER’s only High-tier benefit and comes first; bowel regularity and the satiety-linked weight effect are both Medium and follow.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct time-to-effect aspects, so all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	“Weeks” with the three-month HbA1c note (ER 391), “Within days” for bowel (ER 391) and satiety (ER 391), each with an ER-sourced sub-line.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides a dedicated “Time to effect” bullet, so the section is retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All ten items match the ER’s Expected Benefits subsection headings (ER 148–208).
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present and populated (QRS 521–532).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Only the tier headings survive; every Magnitude: line and mechanistic paragraph is dropped. The retained “conflicted” is the ER’s own hedge, required by item 1.2.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any benefits item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four benefit tiers carry ER items.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All six items match the ER’s risk subsection headings (ER 230–274).
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (QRS 575–586).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Heading text only; the standardised mean difference and confidence interval at ER 236 and the psyllium case reports at ER 242 are absent.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in any risks item; the ER’s gloss “(a compacted mass of indigestible material)” (ER 242) is not carried over.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four risk tiers carry ER items.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Table and cadence derive from Monitoring Protocol & Defining Success (ER 415–431).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER table rows appear with matching targets: fasting glucose, HbA1c, fasting insulin, ApoB, triglycerides, ALT, ferritin with iron studies, hs-CRP, 25-hydroxyvitamin D.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	“Baseline, then 12 weeks, then every 6–12 months; ferritin at 6 months if borderline.” (QRS 705), condensing ER 419.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All items come from the ER’s qualitative marker list (ER 435–440).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All six ER qualitative markers appear as [qualitative_item_1] through [qualitative_item_6] (QRS 714–730).

Issues 22/08/2026 21:10

Pass rate 100.00%. No issues found.

Issues 22/08/2026 21:01

1. 4.5 — Content exceeds one A4 page: The sheet runs to roughly 74 text lines plus eight box chromes (on the order of 1,900px) against the ~1,030px of usable height the print rule provides; the Key Interactions gate, the nine-row Monitoring table, and the three-line action_#_sub and time_#_sub cells are the largest overruns.

Fixes 22/08/2026 21:01

1. 4.5 — At-a-glance shortened: Trimmed the closing risk clause from “Risks are real but largely mechanical, falling away with full soaking, ample fluid, and separation from medication” to “Risks are real but mechanical, falling away with soaking, fluid and separation from medication”, cutting one rendered line.
2. 4.5 — Protocol sub-cells cut to two lines: Dropped the trailing sentences from action_1_sub (the 2 g extract detail), action_2_sub (“Warm water gels faster”) and action_3_sub (“Morning fasted use has no supporting trial”), which were pushing each cell to three lines.
3. 4.5 — Time-to-effect sub-cells cut to two lines: Reduced time_1_sub to “Glycated haemoglobin needs three months to shift” and time_3_sub to “Gel in the stomach delays emptying and increases fullness”, removing the redundant trailing clauses.
4. 4.5 — Key Interactions gate reduced: Trimmed the example lists on the two three-line items — bulk-forming laxatives from “psyllium, methylcellulose, chia” to “psyllium, chia” and anticoagulant supplements from “fish oil, garlic, ginkgo” to “fish oil, ginkgo” — bringing both to two lines while keeping named examples as item 9.5 requires.
5. 4.5 — Monitoring table rows unwrapped: Shortened marker_2_why to “Three-month average glucose”, marker_4_why to “Bile-acid binding lowers cholesterol”, marker_9_why to “Absorption plausibly reduced by the gel” (hedge retained), marker_6_target to “10–26 U/L men, 7–20 U/L women” and marker_7_target to “50–150 ng/mL, saturation 25–35%”, collapsing five two-line rows to one line each.
6. 4.5 — Monitoring cadence condensed: Rewrote to “Baseline, then 12 weeks, then every 6–12 months; ferritin at 6 months if borderline”, fitting a single line without losing any element of the ER schedule.

Issues 22/08/2026 20:51

1. 4.5 — Key Interactions gate over one-page budget: At 9.5pt in the ~312px gate column the eight caution_items (lines 556–563) wrap to roughly 23 lines — five of them three or four lines because full example-drug lists are carried, worst at line 559 (157 characters, five drug categories) — which together with the 13-line stop_items list and the nine-row Monitoring table pushes the sheet past a single A4 page.

Fixes 22/08/2026 20:51

1. 4.5 — Key Interactions example lists condensed: Trimmed the eight caution_items example-drug lists to the shortest set that keeps each interaction identifiable — narrow-therapeutic-index drugs to “levothyroxine, warfarin, digoxin”, over-the-counter medications to “aspirin, ibuprofen, paracetamol”, bulk-forming laxatives to “psyllium, methylcellulose, chia”, mineral/vitamin supplements to “iron, calcium, zinc”, anticoagulant supplements to “fish oil, garlic, ginkgo”, and glucose-lowering supplements to “berberine, chromium, cinnamon”. The gate column drops from roughly 23 to 17 wrapped lines while every ER “(caution; …)” qualifier and at least two named examples per item are retained, as item 9.5 permits.
2. 4.5 — Fluid-restriction contraindication shortened: Rewrote the longest stop_items entry from “Unable to drink 250 ml of fluid per dose, including fluid restriction (advanced heart failure, New York Heart Association Class III–IV; dialysis)” to “Unable to drink 250 ml of fluid per dose (heart failure NYHA Class III–IV, dialysis)”, cutting it from three wrapped lines to two while preserving the 250 ml threshold and the clinical staging.

Issues 22/08/2026 20:44

1. 1.3 — At-a-glance drops ER hedge: The ER Conclusion says “The risks are real but largely mechanical”; [at_a_glance] at QRS line 433 states “Risks are mechanical”, an absolute claim the ER does not support given the allergy and microbial-contamination risks.

Fixes 22/08/2026 20:44

1. 1.3 — At-a-glance hedge restored: Changed [at_a_glance] from “Risks are mechanical and fall away with…” to “Risks are real but largely mechanical, falling away with…”, matching the ER Conclusion’s wording; the summary remains within the 60-word budget at 55 words.

Issues 22/08/2026 20:35

1. 1.1 — Single study cited as “Trials”: [action_1_sub] at line 450 reads “Trials used 2 g of swollen seed extract twice daily”, but ER line 338 attributes that dose to one study only (“Mahidol University work used 2 g of swollen seed extract in 240 ml water twice daily”).
2. 9.5 — Example drug lists dropped entirely: Four ER parenthetical example drug lists are removed rather than trimmed — “antiepileptics (carbamazepine, phenytoin)” (line 557), “sulfonylureas (glipizide, glimepiride, gliclazide)” (line 558), and “antihistamines (loratadine, cetirizine)” plus “proton-pump inhibitors (… omeprazole)” (line 559).

Fixes 22/08/2026 20:35

1. 1.1 — Single study cited as “Trials”: Changed [action_1_sub] from “Trials used 2 g of swollen seed extract twice daily.” to “The trial used 2 g of swollen seed extract twice daily.”, matching the ER’s attribution of that dose to one study.
2. 9.5 — Example drug lists restored: Re-added one trimmed example per dropped ER parenthetical — “antiepileptics (carbamazepine)”, “sulfonylureas (glipizide)”, “antihistamines (loratadine)” and “proton-pump inhibitors (omeprazole)” — in the Key Interactions gate.

Issues 22/08/2026 20:31

1. 4.5 — Content exceeds one A4 page: At the template’s print geometry the sheet runs roughly 1.8 A4 pages; the Key Interactions gate (lines 555–564), the nine-row Monitoring table (lines 602–700), the six Qualitative Assessment items (lines 713–731) and the four-to-five-line protocol sub-lines (lines 450, 461, 472, 489) were carried over at near-ER length instead of being condensed to a per-section budget.

Fixes 22/08/2026 20:31

1. 4.5 — At-a-glance tightened: Condensed [at_a_glance] from 60 to 53 words, dropping “as a family” and rewriting the closing risk clause (“falling away when seeds are fully soaked, taken with ample fluid, and separated from medication” → “fall away with full soaking, ample fluid, and separation from medication”).
2. 4.5 — Protocol sub-lines shortened: Trimmed [action_1_sub], [action_2_sub], [action_3_sub], [time_1_sub] and [time_3_sub] by one wrapped line each (e.g. “Trial dosing was 2 g of swollen seed extract in 240 ml water twice daily” → “Trials used 2 g of swollen seed extract twice daily”).
3. 4.5 — Contraindication fluid item condensed: Reduced the 190-character fluid-restriction gate to 143 characters while keeping the 250 ml threshold and the New York Heart Association Class III–IV staging.
4. 4.5 — Interaction example lists trimmed: Shortened the nested drug examples in four [caution_items] per the “trimmed where needed, never dropped entirely” rule (removed “(carbamazepine, phenytoin)”, “(glipizide, glimepiride, gliclazide)”, “(loratadine, cetirizine)” and “(omeprazole)”); every bullet retains a named example list.
5. 4.5 — Monitoring “Why” column compressed: Rewrote seven of the nine [marker_#_why] cells to single-line phrasing (e.g. “Tracks the fatty liver endpoint the pooled fibre data support” → “Tracks the fatty liver endpoint”) and shortened [monitoring_cadence] from 150 to 117 characters.
6. 4.5 — Qualitative items condensed: Shortened [qualitative_item_1], [qualitative_item_3] and [qualitative_item_5], removing the redundant tails (“with types 3–4 as the target” → “target types 3–4”; “which should decline rather than persist” → “which should decline”).

Issues 22/08/2026 20:23

1. 1.2 / 1.3 — Risk hedge dropped in At-A-Glance: at_a_glance (line 433) states “Risks are mechanical”, while the ER Conclusion (line 464) says “real but largely mechanical”; dropping “largely” softens the risk picture and implies allergy and microbial contamination also fall away with soaking and fluid.
2. 2.6 / 2.9 — Imperative address in Protocol cells: action_2_value (line 458) reads “Soak 10–15 minutes” and action_3_sub (line 472) reads “split before two meals”, both imperatives directed at the reader, where the ER uses non-directive forms (“Soaking at a 1:10 to 1:20 ratio…”, “Split dosing before two meals is what the human trials used”).

Fixes 22/08/2026 20:23

1. 1.2 / 1.3 — Risk hedge restored in At-A-Glance: Changed “Risks are mechanical” to “Risks are largely mechanical” to match the ER Conclusion, and shortened “slows a meal” to “slows meals” to hold the summary at the 60-word limit.
2. 2.6 / 2.9 — Imperative address removed from Protocol: Replaced the imperative action_2_value “Soak 10–15 minutes” with the nominal “10–15 minute soak”, and rewrote action_3_sub from “split before two meals as the trials used” to “the trials split dosing before two meals”.

Issues 22/08/2026 20:15

1. 9.5 — Dropped example drug lists: In the “Over-the-counter medications” caution item (line 559) the ER’s parenthetical example drugs for antihistamines (“loratadine, cetirizine”) and proton-pump inhibitors (“omeprazole”) from ER line 298 are dropped entirely, while the parallel nested lists for antiepileptics and sulfonylureas are preserved at lines 557–558.

Fixes 22/08/2026 20:15

1. 9.5 — Restored example drug lists: In the “Over-the-counter medications” caution item, the ER’s parenthetical example drugs were reinstated — “antihistamines” became “antihistamines (loratadine, cetirizine)” and “proton-pump inhibitors” became “proton-pump inhibitors (omeprazole)”, matching how antiepileptics and sulfonylureas are already handled.

Issues 22/08/2026 20:07

1. 11.4 — Time-to-effect sub duplicates monitoring item: [time_3_sub] at line 511 reads “Fullness and time to hunger after meals preceded by a dose.” — a word-for-word copy of [qualitative_item_4] at line 723 that says nothing about why satiety effects appear “Within days”, spending one-page budget on a sentence the sheet already carries.

Fixes 22/08/2026 20:07

1. 11.4 — Time-to-effect sub rewritten: Replaced [time_3_sub] (line 511), which duplicated [qualitative_item_4] word for word, with “Gel in the stomach delays emptying and increases fullness; the mechanism is meal-dependent rather than systemic.” — drawn from ER lines 166 and 346, so the cell now explains why satiety effects appear within days.